Open Access

Targeting the PCSK9 pathway: where do novel therapies fit in?

Topic: Lipid-Lowering Agents
Organised by PACE-CME - Supported by an unrestricted educational grant from Novartis, Sanofi, Daïchi Sankyo, New Amsterdam & other sponsors

Congress Session

About the speaker

Associate Professor Ann Marie Navar

University of Texas Southwestern Medical Center, Dallas (United States of America)
1 presentation
1 follower

4 more presentations in this session

Introduction: changing paradigms in LDL-c reduction.

Speaker: Professor K. Ray (London, GB)

Thumbnail

LDC-c: new insights into its role as causal risk factor and target for therapy

Speaker: Professor B. Ference (Cambridge, GB)

Thumbnail

Addressing the unmet needs in LDL-c lowering: what can we expect?

Speaker: Professor J. Kastelein (Amsterdam, NL)

Thumbnail

Discussion.

Speaker: Professor K. Ray (London, GB)

Thumbnail

Access the full session

A decade of innovation, guidelines and paradigm shifts in LDL-C management (10th annual symposium)

Speakers: Associate Professor A. Navar, Professor K. Ray, Professor B. Ference, Professor J. Kastelein, Professor K. Ray
Thumbnail

About the event

Image

ESC Congress 2022

26 August - 29 August 2022

Sessions Presentations

This platform is supported by

logo Novo Nordisk